Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.71 |
| ▸ | CA2 | P00918 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Anisic Acid SCHEMBL27576225 | 0.85 | CA1 (0.91) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL1157044 | 0.84 | CA1 (1.00) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL43335 | 0.84 | CA1 (1.00) | CA1CA2NPC1POLBRAB9A | |
| SCHEMBL8353010 | 0.84 | CA1 (0.74) | CA1CA2NPC1POLBRAB9A | |
| Terephthalic Acid SCHEMBL8989156 | 0.84 | CA1 (0.74) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL846287 | 0.82 | CA1 (0.95) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL15548197 | 0.82 | CA1 (0.95) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL1043957 | 0.82 | CA1 (0.95) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL414716 | 0.82 | CA1 (0.95) | CA1CA2NPC1POLBRAB9A | |
| P-Anisic Acid SCHEMBL38654440 | 0.82 | CA1 (0.95) | CA1CA2NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002421-A1 | METHODS AND ASSAYS FOR DETERMINING REDUCED BRCA1 PATHWAY FUNCTION IN A CANCER CELL | THE GENERAL HOSPITAL CORPORATION (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015100257-A1 | METHODS AND ASSAYS FOR DETERMINING REDUCED BRCA1 PATHWAY FUNCTION IN A CANCER CELL | THE GENERAL HOSPITAL CORPORATION (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8202975-B2 | High-risk human papillomavirus detection | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110269134-A1 | Reagents and Methods for Detecting Neisseria Gonorrhoeae | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110160072-A1 | METHOD OF DIAGNOSING NEOPLASMS | CLINICAL GENOMICS PTY. LTD. (AU) | 2011-06-30 | — | — | US | disclosed |
| US-7919249-B2 | use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7816076-B2 | Therapeutic targets in cancer | SAGRES DISCOVERY, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7767387-B2 | Therapeutic targets in cancer | SAGRES DISCOVERY, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090325810-A1 | DETECTION METHOD | CLINICAL GENOMICS PTY. LTD. (AU) | 2009-12-31 | — | — | US | disclosed |
| US-20090317391-A1 | Cancer Related Genes (PTPE) | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20070292886-A1 | REAGENTS AND METHODS FOR DETECTING NEISSERIA GONORRHOEAE | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070282015-A1 | Novel Splice Variants of Human Dkkl1 | CHIRON CORPORATION (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070274990-A1 | Novel Therapeutic Targets in Cancer | MORRIS DAVID W | 2007-11-29 | — | — | US | disclosed |
| US-20070218071-A1 | Novel therapeutic targets in cancer | SAGRES DISCOVERY, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070212351-A1 | Identifying modulators for treatment of cell proliferative disorders via variation in cancer associated polynucleotide expression profiles | SAGRES DISCOVERY, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070161003-A1 | Novel therapeutic targets in cancer | SAGRES DISCOVERY, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20060063193-A1 | Solid phase sequencing of double-stranded nucleic acids | TRUSTEES OF BOSTON UNIVERSITY, THE | 2006-03-23 | — | — | US | disclosed |
| US-20050090434-A1 | Novel therapeutic targets in cancer | BLUE DOT CAPITAL PTE LTD. (SG) | 2005-04-28 | — | — | US | disclosed |
| US-20040166490-A1 | Novel therapeutic targets in cancer | FORWARD VENTURES IV B, L.P. | 2004-08-26 | — | — | US | disclosed |
| US-20040067492-A1 | Reverse transcription on microarrays | MERGEN LIMITED | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160072-A1 | METHOD OF DIAGNOSING NEOPLASMS | APC, DDX21, FABP2 | CA1 1214/4885CA2 2651/4885NPC1 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.